证券日报网讯沃森生物（300142）10月17日在互动平台回答投资者提问时表示，公司严格遵守与股东持 股信息相关的信息披露的规定，依法依规披露股东持股信息，关于公司前10大股东的持股信息请查阅公 司披露的定期报告。公司致力于打造中国自主可控的疫苗产业，以优质产品供应全球市场，持续加大资 源投入，从人才培养、项目引进、市场营销、产品国际注册和临床试验、国际认证、合作生产等多个方 面多元化开展国际业务。公司基于自身丰富的经验，不断探索更多新型合作模式，拓展海外合作的深度 和广度，让创新疫苗惠及更多民众，不断提升公司在国际市场上的影响力，助力全球疫苗可及。关于公 司产品出口、海外合作的相关信息请持续关注公司披露的公告。 ...

公告显示，本次获得约旦的《药品注册证》，标志着沃森生物在中东市场的战略布局取得关键进展，是 公司13价肺炎球菌多糖结合疫苗在国际化进程中取得的重要突破。因公司产品首次在约旦市场实现准 入，关于该疫苗的实际上市时间与销售业绩尚存在一定的不确定性。 本报讯(记者李如是)9月30日，云南沃森生物（300142）技术股份有限公司(以下简称"沃森生物")发布公 告称，子公司玉溪沃森生物技术有限公司生产的13价肺炎球菌多糖结合疫苗于近日收到约旦食品与药品 监督管理局签发的《药品注册证》。 ...

Group 1 - The company is actively pursuing WHO PQ certification for its nine-valent HPV vaccine, aiming to expand its global market presence [1] - The company plans to leverage the international achievements of its bivalent HPV vaccine to build a broader global network [1] - The company is exploring long-term opportunities in international markets, including Europe and the United States, while supporting the global strategy to eliminate cervical cancer [1]

Core Viewpoint - The article highlights the rapid IPO of Zhonghui Biotech, which achieved a listing on the Hong Kong Stock Exchange in just 10 months, setting a record for the fastest project handled by intermediary institutions [2][4]. Company Overview - Zhonghui Biotech, founded by An Youcai, is a newcomer in the vaccine industry, having been established only 10 years ago and currently offering one vaccine on the market [2][6]. - The company’s flu vaccine is the only quadrivalent subunit vaccine available in the domestic market, priced at 319 yuan per dose, making it the most expensive flu vaccine in China [10][11]. Financial Aspects - The IPO raised approximately 383 million HKD, which will alleviate the company's financial pressure, especially as it faces a bank loan repayment of about 400 million yuan within a year [4]. - As of the end of Q1 2025, Zhonghui Biotech had a cash balance of only 115 million yuan [4]. Market Position and Strategy - Zhonghui Biotech aims to position itself as an international company focused on innovation in the vaccine sector, distinguishing itself from competitors by not participating in the price-cutting trend for flu vaccines [3][10]. - The company is expanding its market reach internationally, particularly targeting Southeast Asia and Latin America, and has formed a strategic partnership with Watson Bio for overseas sales [11]. Product Development - Currently, Zhonghui Biotech has 11 vaccines in its pipeline, with 10 in development and one already on the market [10]. - The company is also working on a human diploid rabies vaccine and other products aimed at replacing imported vaccines and leading globally in vaccine technology [12][13]. Leadership and Expertise - An Youcai, the founder, transitioned into the vaccine industry from a non-biological background, leveraging 15 years of entrepreneurial experience to enhance his expertise in immunology and vaccine development [6][8]. - The company has attracted experienced scientists to its team, including those who have previously worked on significant vaccine projects [7].

Core Viewpoint - Zhifei Biological's 26-valent pneumococcal conjugate vaccine (PCV26) has initiated Phase I clinical trials in Australia, marking a significant step in enhancing the global influence of Chinese vaccines [1] Group 1: Vaccine Development - The PCV26 is the only high-valent vaccine developed independently in China that has entered clinical trials [1] - The vaccine is progressing smoothly in domestic clinical trials, indicating strong development capabilities [1] Group 2: Market Positioning - The PCV26 is expected to synergize with Zhifei's existing 23-valent pneumococcal polysaccharide vaccine and the 15-valent pneumococcal conjugate vaccine, covering the entire age spectrum from infants to the elderly [1] - This strategic positioning aims to enhance Zhifei's status in the global pneumococcal vaccine market [1] Group 3: International Expansion - The initiation of overseas clinical trials signifies a multi-dimensional upgrade in Zhifei's pneumonia product matrix, establishing a more complete and competitive product system [1] - This move is a solid step towards internationalization, laying a stable foundation for market expansion and deepening in the global arena [1]

Core Viewpoint - Wantaibio is actively advancing the WHO PQ certification process for its nine-valent HPV vaccine following its approval, leveraging its existing international achievements with the two-valent HPV vaccine [1] Group 1 - The company has initiated a structured plan for nationwide bidding and procurement work for the nine-valent HPV vaccine after its approval [1] - Wantaibio is confident in accelerating the overseas access and expansion of the nine-valent HPV vaccine, supported by its global network and prior success in over 20 countries with its two-valent HPV vaccine [1] - The two-valent HPV vaccine has been included in immunization programs in eight countries, showcasing the company's established international presence [1]